Skip to main content

Qiagen to Distribute JCSG's Protein Crystallization Screens; Shareholders OK Digene Buy

NEW YORK (GenomeWeb News) — Qiagen said today it will distribute protein crystallization screens developed by the Joint Center for Structural Genomics.

Separately today the company said that its shareholders have approved its $1.6 billion acquisition of Digene.

Terms of Qiagen’s agreement with JCSG call for the company to distribute the new screens, known as the JCSG Core Suites I-IV. The company said these screens resulted from JCSG’s analysis of more than 500,000 high-throughput crystallization experiments.

"These new screens are the result of mining the vast database of crystallization experiments performed by the JCSG,” said Qiagen’s global business director of proteins Kai te Kaat.

JCSG is one of the Protein Structure Initiative’s Genomics Production Centers, and is funded by the National Institute for General Medical Sciences.

JCSG principal investigator Ian Wilson said the supplier agreement with Qiagen “enables the fruits of the NIH Protein Structure Initiative to become available to all structural biologists and allow them the opportunity to enhance their own individual success rates in protein crystallization."

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.